23andMe Continuing GWAS into Disease Factors; Official 'Optimistic' Over FDA Talks

The company continues to leverage its patient database of cohorts to conduct research into genetic factors in disease, the predictive power of its tests, and how consumers are using information gleaned from their test results, a company official said today.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories